drugset / Trial / NCT02897206

Imipenem Prophylaxis in Patients With Acute Pancreatitis

NCT02897206

RandomizedParallel-groupQuadruple-blindPrevention

Summary

This is a prospective, single-center, randomized, placebo-controlled, double-blind clinical trial that aims to investigate the beneficial and harmful effects of prophylactic use of imipenem in patients with predicted severe acute pancreatitis. All patients with first attack of acute pancreatitis, an onset of disease less than 72h before admission, and an APACHE II score ≥ 8 calculated within the first 24h from admission will be enrolled.

Timeline

Start
2014-10
Primary completion
2016-12
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Subject IMIPENEM ANHYDROUS Small molecule 500 mg Intravenous

Indications